YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1

Journal of the National Cancer Institute

Volumn 95, Issue 7, 2003, Pages 516-525

  Yeo, Eun Jin ^a   Chun, Yang Sook ^a   Cho, Young Suk ^a   Kim, Jinho ^a   Lee, June Chul ^a   Kim, Myung Suk ^a   Park, Jong Wan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG VEHICLE; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PROTEIN INHIBITOR; VASCULOTROPIN; 3-(5'-HYDROXYMETHYL-2'-FURYL)-1-BENZYLINDAZOLE; CD31 ANTIGEN; ENDOTHELIAL CELL GROWTH FACTOR; GANGLIOSIDE GM1; GANGLIOTETRAOSYLCERAMIDE; HIF1A PROTEIN, HUMAN; INDAZOLE DERIVATIVE; LYMPHOKINE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG TARGETING; GENE ACTIVITY; GENE EXPRESSION; GENE INDUCTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; STATISTICAL ANALYSIS; STOMACH CARCINOMA; THROMBOCYTE AGGREGATION INHIBITION; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; VASOCONSTRICTION; ANIMAL; CARCINOMA; CELL CULTURE; CELL HYPOXIA; CULTURE MEDIUM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; KIDNEY TUMOR; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE MUTANT; NATURAL KILLER CELL; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; RAT; SERODIAGNOSIS; STOMACH TUMOR; UTERINE CERVIX TUMOR; VASCULARIZATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; G(M1) GANGLIOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; INDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOKINES; MALE; MICE; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PRECIPITIN TESTS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037414180     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.7.516     Document Type: Article

References (30)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Nad Cancer Inst 2001;93:266-76.
2. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649-60.
3. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-70.
4. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
5. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
6. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
7. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
8. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
9. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-206.
10. Huang LE, Gu J, Schau M, Bunn HF. Regulation of bypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
11. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
12. Zhong H, De Matzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
13. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
14. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104-9.
15. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997;320:161-6.
16. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999; 127:195-203.
17. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-54.
18. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci 2001;114:4051-61.
19. Chun YS, Choi E, Kim TY, Kim MS, Park JW. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J 2002;362:71-9.
20. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 2002;90,E25-33.
21. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, Yoshikai Y. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 2002;99:573-8.
22. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316.
23. Klein AS, Plata F, Jackson MJ, Shin S. Cellular tumorigenicity in nude mice. Role of susceptibility to natural killer cells. Exp Cell Biol 1979;47:430-45.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
25. Griffioen AW, Barendsz-Janson AF, Mayo KH, Hillen HF. Angiogenesis, a target for tumor therapy. J Lab Clin Med 1998;132:363-8.
26. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol 2001;19:257-62.
27. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757-63.
28. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84:4226-33.
29. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 1998;54:962-7.
30. Rothermund L, Friebe A, Paul M, Koesling D, Kreutz R. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br J Pharmacol 2000;130:205-8.